EXTENDED REPORT

Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women

S Kluzek,1,2 M T Sanchez-Santos,1,2 K M Leyland,1,2 A Judge,1,3 T D Spector,4 D Hart,4 C Cooper,1,3 J Newton,1,2 N K Arden1,2,3

ABSTRACT

Objective To assess whether joint pain or radiographic osteoarthritis (ROA) of the knee and hand is associated with all-cause and disease-specific mortality in middle-aged women.

Methods Four subgroups from the prospective community-based Chingford Cohort Study were identified based on presence/absence of pain and ROA at baseline: (Pain−/ROA−; Pain+/ROA−; Pain−/ROA+; Pain+/ROA +). Pain was defined as side-specific pain in the preceding month, while side-specific ROA was defined as Kellgren–Lawrence grade ≥2. All-cause, cardiovascular disease (CVD) and cancer-related mortality over the 23-year follow-up was based on information collected by the Office for National Statistics. Associations between subgroups and all-cause/cause-specific mortality were assessed using Cox regression, adjusting for age, body mass index, typical cardiovascular risk factors, occupation, past physical activity, existing CVD disease, glucose levels and medication use.

Results 821 and 808 women were included for knee and hand analyses, respectively. Compared with the knee Pain−/ROA− group, the Pain+/ROA− group had an increased risk of CVD-specific mortality (HR 2.93 (95% CI 1.47 to 5.85)), while the knee Pain+/ROA+ group had an increased HR of 1.97 (95% CI 1.23 to 3.17) for all-cause and 3.57 (95% CI 1.53 to 8.34) for CVD-specific mortality. We found no association between hand OA and mortality.

Conclusion We found a significantly increased risk of all-cause and CVD-specific mortality in women experiencing knee pain with or without ROA but not ROA alone. No relationship was found between hand OA and mortality risk. This suggests that knee pain, more than structural changes of OA is the main driver of excess mortality in patients with OA.

INTRODUCTION

Osteoarthritis (OA) is the most common form of arthritis and a significant contributor of musculoskeletal disability burden in the developed world.1 In the population aged above 35 years, one in four reports frequent knee pain and have evidence of radiographic knee OA (KOA).2 The lifetime risk of receiving a total knee replacement at age 50 is 8.1% for men and 10.8% for women.2 The prevalence of symptomatic hand OA is 8.2% and 15.9% in men and women, respectively.4

There is growing evidence that low-grade systemic inflammation, linked with adipose tissue, is associated with joint pain,5–7 incidence of radiographic changes,6 8 development of cardiovascular disease (CVD)10–12 and also have a role in the cancer pathogenesis.13 Compared with individuals with no OA, participants with total joint replacements have a 26% increased risk of CVD.14 Furthermore, a younger middle-aged population with OA have a fivefold increased prevalence of metabolic syndrome.15 16

The strongest evidence of a relationship between OA and mortality comes from an observational study where patients with symptomatic radiographic KOA and/or hip OA were selected and found to be at increased mortality risk compared with general population.17 A more recent study demonstrates a borderline significant association between excess mortality and symptomatic (but not radiographic) KOA alone.18 19 Hand OA was associated with a risk of premature CVD death in the Finnish population aged 30 years and older.19–21 In contrast, a more recent publication demonstrates no association with an excess mortality and hand OA, despite increased risk of coronary heart disease events in a population with symptomatic hand OA.22

It is currently unclear whether symptomatic or radiographic only OA is associated with excess mortality. The aim of our study was to examine the relationship between KOA and hand OA and the risk of mortality in a longitudinal community-based cohort with 23 years of follow-up. Participants were divided into four subgroups based on presence or absence of pain and radiographic osteoarthritis (ROA).

METHODS

Study population

Characteristics of the Chingford study have been described in detail previously.23 Briefly, in Chingford, North London, UK, all women aged 45–64 years from the register of a large general practice were contacted in 1988–1989 and asked to participate in a population-based study to evaluate risk factors for osteoporosis and OA. Among 1353 women contacted, 1003 (78% response rate) preferred to participate.
attended the baseline visit and have since been examined annually. This cohort has been shown to be representative of women in England.\textsuperscript{23}

**Inclusion criteria**

We included 821 women for knee and 808 for hand analyses with available data on both pain and radiographic KOA or hand OA. Women with the following diseases (n=43) at baseline or any point of follow-up were excluded from analysis: rheumatoid arthritis, psoriatic arthritis, gout, Paget’s disease, polio, cerebral palsy and chronic inflammatory demyelinating neuropathy. Two participants were excluded due to lack of time-to-death data. Further, 137 women for knee and 150 for hand analyses were excluded due to lack of pain and/or radiographic data at baseline (figure 1). Characteristics of the participants without baseline radiographic or pain data were similar with those included for analyses.

**Assessment of mortality**

The outcomes of interest were all-cause and cause-specific mortality from CVD and cancer, based on available data up to August 2014. The Health and Social Care Information Centre provided detailed mortality information on the Chingford cohort based on the information collected by the Office for National Statistics from civil registration records. The cause of death was based on the information from death certificates. For the cause-specific mortality, we reviewed all CVD and cancer-related deaths data from death certificates. In seven cases of cardiovascular mortality, the cause of death was changed to cancer-related mortality, if the direct cause of death was a complication of cancer or its treatment. The cumulative number of deaths over the 23 years (median 21.7 years (IQR: 21.2–22.3)) of follow-up was 223 women (22.2%) out of the total sample of 1003 women. CVD mortality accounted for 29\% (n=64), cancer for 45\% (n=100) and other diseases for 26\% (n=59) of all-cause mortality. Time-to-event was assessed from year 3 until death, or the end of the follow-up (15 August 2014).

**Assessment of joint-specific OA and pain**

A physical examination at baseline (year 1) was performed to assess anteroposterior (AP) radiographs of the hands and weight-bearing AP radiographs of the knees. The protocols for radiographic grading and reproducibility for both KOA and hand OA and for this study have been previously reported.\textsuperscript{24–27} Women were classified as having radiographic KOA if they had a Kellgren–Lawrence (K/L) OA grade of 2 or more in at least one knee at baseline. Hand radiographs were also graded for OA. Summary scores of distal interphalangeal, proximal interphalangeal and first carpometacarpal joints were defined as the number of joints with K/L grade \(\geq 2\), while radiographic hand OA in any hand joint was defined as positive if the K/L score in at least one joint was \(\geq 2\).

Knee and hand pain was assessed at year 3 as part of a self-administered questionnaire.\textsuperscript{28} Women were asked if they had

![Figure 1](image-url)  
**Figure 1** A flow diagram of participants included and excluded for each analysis. *Rheumatoid arthritis, psoriatic arthritis, gout, Paget’s disease, polio, cerebral palsy and chronic inflammatory demyelinating neuropathy.
experienced any knee/hand pain in the past month and the number of days this had occurred. Knee/hand pain was classified as positive for either knee/hand if ‘yes’ and ‘more than 0 days’ were reported.

Joint-specific OA and pain was classified into four subgroups based on presence and absence of pain and ROA: 1. Neither ROA nor pain (Pain−/ROA−: reference category). 2. ROA (Pain−/ROA+). 3. Pain only (Pain+/ROA−). 4. Painful ROA (Pain+/ROA+: joint(s) with ROA and pain in the same side).

Women with ROA only in one side and pain only in the contralateral side were classified as having ROA+/Pain− only.

Potential confounders
We assessed information on potential confounders at year 3. Sociodemographic covariates included age and occupation (‘Manual’ vs ‘Non-manual’). Health-related behaviours were physical activity (PA) at age 30 and smoking. PA at age 30 was assessed by the following question: ‘Were you a physically active person at age 30?’ Smokers were classified as never smoked/ex-smoker or currently smoking. Current and past CVD disease was ascertained by asking the women if they had any CVD disease. We included all risk factors for heart disease that are part of the Framingham Heart Study Risk Assessment.29 The biological factors included were body mass index (BMI), systolic blood pressure (BP), total and high-density lipoprotein (HDL) cholesterol and glucose. BMI was calculated at baseline and divided into two groups: ‘non-obese’ (BMI <30 kg/m²) and ‘obese’ (BMI ≥30 kg/m²). Total and HDL cholesterol and glucose were measured by fasting serum samples taken.30 For the analysis, systolic BP total and HDL cholesterol and glucose were treated as continuous variables. BP medication, non-steroidal anti-inflammatory drugs (NSAIDs) and hormone replacement therapy (HRT) use were coded as dichotomous variables with a value of 1 if the women reported taking the medication and 0 otherwise.

Statistical analysis
All analyses were conducted using Stata V13 statistical software (StataCorp, College Station, Texas, USA) and took place separately for knee and hand. Multiple imputation using chained equations was used to investigate the impact of missing potential confounders, while 100 imputed datasets were generated using all potential confounders (including all-cause mortality and log-transformed survival time) and estimated parameters were combined using Rubin’s rules. Kaplan–Meier survival curves for all-cause mortality in joint-specific OA and pain subgroups were estimated.

The association between joint-specific OA and pain subgroups (knee and hand) and all-cause and cause-specific mortality was assessed using Cox proportional hazards regression models to estimate HRs and 95% CIs. Three models were used to assess this association: Model (1) was age-adjusted. Model (2) added risk factors from Framingham Risk Score (smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication). Model (3) added the remaining potential confounders (occupation, HRT use, past PA, BMI, current/previous CVD disease, non-acytlesalicylic acid (ASA) NSAIDs and glucose levels).

In the analyses of specific cause of death, deaths attributed to other causes were treated as censored at the time of death. Proportional hazards assumption was examined by Schoenfeld residuals. There was no evidence showing that the hazards were not proportional over the follow-up period studied.

Four sensitivity analyses were conducted. First, we excluded women who underwent joint-specific surgery at any point during follow-up. Second, all deaths occurring during the first 12 months of follow-up were excluded. Third, with a radiographic hand OA defined as positive if the K/L score in at least two joints was ≥2. Forth, with available crude measures of PA, this was assessed by the following question, ‘How many times per week do you engage in activity that makes you sweat?’

RESULTS
From 1993 to 2014 (median follow-up of 21.7 years (range: 21.2–22.3)), 166 and 163 deaths (~20%) were confirmed by death certificate among the KOA and hand OA and pain study sample, respectively. Potential confounders according to KOA and hand OA and pain categories are presented in tables 1 and 2, respectively. Compared with women without OA (Pain−/ROA−), women with ROA (Pain+ and Pain−) were older and had higher systolic BP levels (tables 1 and 2). Women with painful knee (ROA+ or ROA−) were more likely to use non-ASA NSAIDs (table 1). Women with knee or hand pain (Pain+/ROA−) were also more likely to be using HRT medication, compared with the other subgroups.

Kaplan–Meier survival curves for all-cause mortality according to KOA and pain (figure 2A) and hand OA and pain categories (figure 2B) are presented in figure 2. Women with painful knee/hand OA had a greater risk of all-cause mortality compared with women with neither knee/hand pain nor ROA (log-rank test p<0.001).

Results from Cox proportional hazards model estimating the mortality risk according to KOA and hand OA and pain categories are shown in tables 3 and 4. In the age-adjusted model, women with knee pain and no ROA had a 49% increased risk of dying from all-cause mortality, compared with those with neither knee pain nor ROA (HR 1.49 95% CI 1.04 to 2.14; p=0.029). The mortality risk was stronger among women with painful knee ROA, reaching a 97% increase in mortality risk in an age-adjusted model (HR 1.97 95% CI 1.23 to 3.17; p=0.005) (Model 1; table 3).

After adjustment for the factors from Framingham Risk Score Factors (Model 2; table 3), the HRs increased slightly for painful knee subgroups (ROA+: ROA−) (1.55 (95% CI 1.07 to 2.22) and 2.06 (95% CI 1.27 to 3.33), respectively) (Model 2; table 3). The relationship remained unchanged even after further adjusting for all other covariates (Model 3; table 3). In contrast, knee ROA alone was not associated with mortality in any of the three models.

The magnitude of association between knee pain subgroups (Pain+/ROA− and Pain+/ROA+) and mortality was the strongest for CVD-specific mortality in all models. Compared with women with neither knee pain nor ROA, the HR associated with knee pain only (Pain+/ROA−) was 3.25 (95% CI 1.64 to 6.43) and with painful knee ROA (Pain+/ROA+) was 4.19 (95% CI 1.87 to 9.40), after adjustment for Framingham Risk Score factors (Model 2; table 3). Further inclusion of all other covariates produced an almost negligible reduction in the HR for CVD-specific mortality (Model 3; table 3). No statistically significant associations were found for cancer-specific mortality.

Additionally, there were no associations between hand pain, with or without ROA, and all-cause or cause-specific mortality after adjustment for other covariates (table 4).

No substantial differences in the results were observed when women who died during the first 12 months of follow-up...
DISCUSSION

In this prospective community-based study of middle-aged women, we found a significant association between knee pain, with or without ROA, and an increased risk of all-cause and CVD-specific mortality. We found no association between knee ROA only (Pain−/ROA+) and decreased survival, although subjects with symptomatic ROA (Pain+/ROA+) had the highest risk of both all-cause and CVD-specific mortality. No relationship was found between hand OA and mortality risk.

There are conflicting results between observational studies on the impact of KOA and hand OA on early mortality. Cerhan et al found that ROA of hands, knees and the cervical spine was associated with decreased survival of middle-aged women who worked in the radium dial-painting industry, when compared with participants without ROA. A systematic review on this subject found moderate evidence of increased mortality among participants with OA compared with the general population. The main limitations of the previous studies include:

- Relatively short follow-up,
- Selection towards participants with symptomatic radiographic OA,
- Comparison with controls from population mortality registers or participants with no ROA, with no study using a comparison group without pain and ROA.

Nüesch et al used a large selected population-based sample of men and women with symptomatic radiographic knee and/or hip OA and compared age and sex standardised mortality ratios after a median of 14 years’ follow-up. They reported a significant excess in all-cause, CVD-related and dementia-related mortality. Liu et al found that participants from two different cohorts of patients consulting health professionals for their OA were not at higher risk of death than the general population (mean follow-up time below 7 years). Hawker et al showed that increased walking disability, use of walking aids and poor baseline function are associated with excess all-cause mortality in individuals with hip OA and KOA symptoms. The main limitations of the previous studies include:

- Relatively short follow-up,
- Selection towards participants with symptomatic radiographic OA,
- Comparison with controls from population mortality registers or participants with no ROA, with no study using a comparison group without pain and ROA.

This paper confirms strong independent association between painful knee (but not hand) OA and excess mortality. This relationship is independent from the majority of known CVD risk factors and not attenuated by non-ASA NSAIDs use, which corresponds with previous findings.

Table 1 Descriptive characteristics across knee status categories

| Characteristic | Neither ROA nor pain (n=524) | ROA only (n=64) | Pain only (n=176) | Symptomatic OA (n=57) | p Value |
|---------------|------------------------------|----------------|-----------------|----------------------|---------|
| Age, years, mean (SD) | 55.2 (5.8) | 58.7 (6.3) | 56.4 (5.8) | 59.6 (4.9) | 0.000 |
| Occupation, n (%) | | | | | 0.042 |
| Manual | 79 (15.1) | 11 (17.2) | 40 (22.7) | 8 (8.8) |
| Non-manual | 440 (84.0) | 52 (81.3) | 135 (76.7) | 52 (91.2) |
| HRT, n (%) | | | | | 0.045 |
| No | 343 (65.5) | 44 (68.8) | 100 (56.8) | 39 (68.4) |
| Yes | 164 (31.3) | 16 (25.0) | 74 (42.1) | 17 (29.8) |
| Smoking, n (%) | | | | | 0.706 |
| Never/ex-smoker | 401 (76.5) | 53 (82.8) | 137 (77.8) | 45 (79.0) |
| Smoker | 123 (23.5) | 11 (17.2) | 39 (22.2) | 12 (21.1) |
| Physical activity at age 30, n (%) | | | | | 0.328 |
| No | 101 (19.3) | 13 (20.3) | 25 (14.2) | 8 (14.0) |
| Yes | 413 (78.8) | 50 (78.1) | 150 (85.2) | 49 (86.0) |
| Body mass index, n (%) | | | | | 0.002 |
| Non-obese (<30 kg/m²) | 316 (60.3) | 39 (60.9) | 118 (67.1) | 34 (59.7) |
| Obese (≥30 kg/m²) | 41 (7.8) | 14 (21.9) | 25 (14.2) | 13 (22.8) |
| Previous CVD disease, n (%) | | | | | 0.436 |
| No | 489 (93.3) | 58 (90.6) | 163 (92.6) | 53 (93.0) |
| Yes | 18 (3.4) | 2 (3.1) | 11 (6.3) | 3 (5.3) |
| BP medication, n (%) | | | | | 0.008 |
| No | 454 (86.6) | 51 (79.7) | 149 (84.7) | 40 (70.2) |
| Yes | 70 (13.4) | 13 (20.3) | 27 (15.3) | 17 (29.8) |
| Non-ASA NSAIDs medication, n (%) | | | | | 0.010 |
| No | 507 (96.8) | 63 (98.4) | 163 (92.6) | 51 (89.5) |
| Yes | 17 (3.2) | 1 (1.6) | 13 (7.4) | 6 (10.5) |
| Systolic BP, mm Hg, mean (SD)* | 124.8 (20.5) | 129.7 (17.6) | 127.1 (17.7) | 132.8 (19.7) | 0.029 |
| Total cholesterol, mg/dL, mean (SD)* | 6.6 (1.4) | 6.7 (1.3) | 6.8 (1.4) | 7.1 (1.2) | 0.072 |
| HDL-cholesterol, mg/dL, mean (SD)* | 1.7 (0.4) | 1.6 (0.4) | 1.7 (0.4) | 1.7 (0.5) | 0.263 |
| Glucose, mmol/L, mean (SD) | 4.9 (0.6) | 5.0 (0.8) | 4.9 (0.7) | 5.1 (0.6) | 0.130 |

*Framingham Risk Score Factors.
BP, blood pressure; CVD, cardiovascular disease; HDL, High-density lipoprotein; HRT, hormone replacement therapy; NSAIDs, non-steroidal anti-inflammatory drugs; OA, Osteoarthritis; ROA, radiographic osteoarthritis.

Bold indicates all significant p value of 0.05.
(n=2), or when women who underwent knee replacement (for knee analysis) during the follow-up (n=29) were excluded (data not shown).

KLUEZ S, et al. Ann Rheum Dis 2016;75:1749–1756. doi:10.1136/annrheumdis-2015-208056
We have found that any self-reported knee pain in the past month, with or without radiographic KOA changes, but not symptomatic hand OA or radiographic KOA alone, is a significant predictor of early CVD mortality. There are number of plausible explanations for our findings, which are not mutually exclusive. The most biologically plausible mechanism for

**Table 2** Descriptive characteristics across hand status categories

| Characteristic                  | Neither ROA nor pain (n=416) | ROA only (n=166) | Pain only (n=127) | Symptomatic OA (n=99) | p Value |
|---------------------------------|------------------------------|------------------|------------------|----------------------|---------|
| Age, years, mean (SD)           | 54.0 (5.5)                   | 59.3 (5.5)       | 55.4 (5.3)       | 60.0 (5.1)           | 0.000   |
| Occupation, n (%)               |                              |                  |                  | 0.688                |         |
| Manual                          | 70 (16.8)                    | 24 (14.5)        | 24 (18.9)        | 14 (14.1)            |         |
| Non-manual                      | 341 (82.0)                   | 141 (84.9)       | 103 (81.1)       | 85 (85.9)            |         |
| HRT, n (%)                      |                              |                  |                  | 0.012                |         |
| No                              | 271 (65.1)                   | 114 (68.7)       | 67 (52.8)        | 64 (64.7)            |         |
| Yes                             | 130 (31.3)                   | 46 (27.7)        | 58 (45.7)        | 34 (34.3)            |         |
| Smoking, n (%)*                 |                              |                  |                  | 0.996                |         |
| Never/ex-smoker                 | 323 (77.6)                   | 130 (78.3)       | 98 (77.2)        | 77 (77.8)            |         |
| Smoker                          | 93 (22.4)                    | 36 (21.7)        | 29 (22.8)        | 22 (22.2)            |         |
| Physical activity at age 30, n (%) | 331 (79.6) | 128 (77.1) | 110 (86.6) | 82 (82.8) | 0.176 |
| Body mass index, n (%)          |                              |                  |                  | 0.272                |         |
| Non-obese (<30 kg/m²)           | 225 (54.1)                   | 110 (66.3)       | 85 (66.9)        | 77 (77.8)            |         |
| Obese (≥30 kg/m²)               | 40 (9.6)                     | 26 (15.7)        | 17 (13.4)        | 8 (8.1)              |         |
| Previous CVD disease, n (%)     | 384 (92.3)                   | 154 (92.8)       | 121 (95.3)       | 93 (93.9)            | 0.901   |
| Yes                             | 17 (4.1)                     | 6 (3.6)          | 4 (3.2)          | 5 (5.1)              |         |
| BP medication, n (%)*           |                              |                  |                  | 0.085                |         |
| No                              | 360 (86.5)                   | 131 (78.9)       | 110 (86.6)       | 80 (80.8)            |         |
| Yes                             | 56 (13.5)                    | 35 (21.1)        | 17 (13.4)        | 19 (19.2)            |         |
| Non-ASA NSAIDs medication, n (%) | 404 (97.1) | 154 (92.8) | 121 (95.3) | 93 (93.9) | 0.110 |
| No                              | 404 (97.1)                   | 154 (92.8)       | 121 (95.3)       | 93 (93.9)            |         |
| Yes                             | 12 (2.9)                     | 12 (7.2)         | 6 (4.7)          | 6 (6.1)              |         |
| Systolic BP, mm Hg, mean (SD)*  | 122.6 (18.4)                 | 130.7 (19.9)     | 127.4 (20.1)     | 132.8 (21.3)         | 0.000   |
| Total cholesterol, mg/dL, mean (SD)* | 6.5 (1.4) | 7.0 (1.3) | 6.7 (1.3) | 7.1 (1.3) | 0.000 |
| HDL-cholesterol, mg/dL, mean (SD)* | 1.7 (0.4) | 1.7 (0.5) | 1.8 (0.5) | 1.7 (0.4) | 0.168 |
| Glucose, mmol/L, mean (SD)      | 4.9 (0.7)                    | 5.0 (0.7)        | 4.9 (0.5)        | 5.0 (0.8)            | 0.184   |

*Framingham Risk Score Factors.
BP, blood pressure; CVD, cardiovascular disease; HDL, High-density lipoprotein; HRT, hormone replacement therapy; NSAIDs, non-steroidal anti-inflammatory drugs; OA, Osteoarthritis; ROA, radiographic osteoarthritis.

Figure 2  All-cause mortality stratified by (A) knee status; and (B) hand status. Kaplan–Meier survival plots of all-cause mortality up to 23 years. OA, osteoarthritis; ROA, radiographic osteoarthritis.
the causal association is that the knee pain results in sedentary behaviour, poor cardiovascular fitness and early mortality. This is supported by some observational studies\(^1\)\(^9\)\(^13\)\(^37\) and by the fact that only 7.7% women with KOA meet recommended PA guidelines.\(^38\) However, an alternative pathway might be presented where painful KOA is an early sign of metabolic dysregulation, leading to CVD problems and premature death. Adipose tissue-associated inflammation is considered to be a common mechanism precipitating development of CVD and painful OA.\(^8\)\(^9\)\(^13\)\(^94\) Women with KOA have higher levels of markers of atherosclerosis.\(^41\) PA is also an important mediator of this inflammatory response\(^42\) and inactivity linked with painful KOA might accelerated metabolic dysregulation.\(^43\) The pain in KOA fluctuates\(^2\) and people commonly limit the activities associated with their symptoms and perceive PA to lead to the disease progression.\(^44\)\(^45\) Despite, clear evidence suggesting that PA improves pain, quality of life and minimises disability in individuals with KOA,\(^47\) we lack evidence supporting that any interventions in patients with KOA improve PA levels or cardiovascular fitness in the longer term.\(^48\)\(^49\)

To our knowledge, this is the first longitudinal prospective community-based cohort with over two decades follow-up

### Table 3 Number of deaths (n) and HR (95% CI) of all-cause and disease-specific mortality by knee OA categories

| Outcome          | Knee OA status          | Model 1 |         |         |         | Model 2 |         |         |         | Model 3 |         |         |
|------------------|-------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
|                  | No. of deaths (%)       | HR      | 95% CI  | p Value | HR      | 95% CI  | p Value | HR      | 95% CI  | p Value |
| All-causes       | Neither ROA nor pain    | 1.00    | 1.00    | 1.00    |         |         |         |         |         |         |
|                  | ROA only                | 0.95    | 0.54 to 1.69 | 0.865 | 1.01    | 0.57 to 1.80 | 0.968 | 1.05    | 0.58 to 1.88 | 0.876 |
|                  | Pain only               | 1.49    | 1.04 to 2.14 | 0.029 | 1.55    | 1.07 to 2.22 | 0.019 | 1.44    | 0.99 to 2.08 | 0.055 |
|                  | Painful ROA             | 1.97    | 1.23 to 3.17 | 0.005 | 2.06    | 1.27 to 3.33 | 0.003 | 1.97    | 1.20 to 3.22 | 0.007 |
| CVD disease      | Neither ROA nor pain    | 1.00    | 1.00    | 1.00    |         |         |         |         |         |         |
|                  | ROA only                | 0.94    | 0.38 to 3.43 | 0.811 | 1.47    | 0.48 to 4.49 | 0.498 | 1.45    | 0.47 to 4.48 | 0.521 |
|                  | Pain only               | 2.78    | 1.43 to 5.41 | 0.003 | 3.25    | 1.64 to 6.43 | 0.001 | 2.93    | 1.47 to 5.85 | 0.002 |
|                  | Painful ROA             | 3.98    | 1.81 to 8.76 | 0.001 | 4.19    | 1.87 to 9.40 | 0.001 | 3.57    | 1.53 to 8.34 | 0.003 |
| Cancer disease   | Neither ROA nor pain    | 1.00    | 1.00    | 1.00    |         |         |         |         |         |         |
|                  | ROA only                | 0.98    | 0.48 to 2.41 | 0.860 | 1.11    | 0.49 to 2.51 | 0.801 | 1.10    | 0.48 to 2.51 | 0.818 |
|                  | Pain only               | 1.23    | 0.72 to 2.12 | 0.444 | 1.23    | 0.72 to 2.12 | 0.451 | 1.12    | 0.64 to 1.94 | 0.683 |
|                  | Painful ROA             | 1.17    | 0.49 to 2.78 | 0.719 | 1.33    | 0.56 to 3.16 | 0.523 | 1.18    | 0.49 to 2.88 | 0.712 |

Model 1: adjusted for age.
Model 2: Model 1+Smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication (Framingham Risk Score Factors).
Model 3: Model 2+occupation, BMI, HRT use, past physical activity, current/previous CVD disease, non-ASA NSAIDs and glucose levels.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, High-density lipoprotein; HRT, hormone replacement therapy; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; ROA, radiographic osteoarthritis.

### Table 4 Number of deaths (n) and HR (95% CI) of all-cause and disease-specific mortality by hand OA categories

| Outcome          | Hand OA status          | Model 1 |         |         |         | Model 2 |         |         |         | Model 3 |         |         |
|------------------|-------------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
|                  | No. of deaths (%)       | HR      | 95% CI  | p Value | HR      | 95% CI  | p Value | HR      | 95% CI  | p Value |
| All-causes       | Neither ROA nor pain    | 1.00    | 1.00    | 1.00    |         |         |         |         |         |         |
|                  | ROA only                | 0.94    | 0.62 to 1.41 | 0.754 | 0.86    | 0.57 to 1.30 | 0.465 | 0.91    | 0.60 to 1.39 | 0.667 |
|                  | Pain only               | 1.02    | 0.64 to 1.65 | 0.920 | 1.02    | 0.63 to 1.64 | 0.947 | 0.98    | 0.60 to 1.60 | 0.946 |
|                  | Painful ROA             | 1.13    | 0.72 to 1.77 | 0.591 | 1.05    | 0.67 to 1.65 | 0.835 | 1.05    | 0.66 to 1.66 | 0.850 |
| CVD disease      | Neither ROA nor pain    | 1.00    | 1.00    | 1.00    |         |         |         |         |         |         |
|                  | ROA only                | 0.94    | 0.62 to 1.41 | 0.754 | 0.86    | 0.57 to 1.30 | 0.465 | 0.91    | 0.60 to 1.39 | 0.667 |
|                  | Pain only               | 1.54    | 0.71 to 3.33 | 0.276 | 1.66    | 0.75 to 3.66 | 0.210 | 1.53    | 0.67 to 3.50 | 0.313 |
|                  | Painful ROA             | 0.80    | 0.34 to 1.91 | 0.620 | 0.76    | 0.32 to 1.82 | 0.541 | 0.75    | 0.30 to 1.87 | 0.539 |
| Cancer disease   | Neither ROA nor pain    | 1.00    | 1.00    | 1.00    |         |         |         |         |         |         |
|                  | ROA only                | 0.94    | 0.62 to 1.41 | 0.754 | 0.86    | 0.57 to 1.30 | 0.465 | 0.91    | 0.60 to 1.39 | 0.667 |
|                  | Pain only               | 1.54    | 0.71 to 3.33 | 0.276 | 1.66    | 0.75 to 3.66 | 0.210 | 1.53    | 0.67 to 3.50 | 0.313 |
|                  | Painful ROA             | 0.80    | 0.34 to 1.91 | 0.620 | 0.76    | 0.32 to 1.82 | 0.541 | 0.75    | 0.30 to 1.87 | 0.539 |

Model 1: adjusted for age.
Model 2: Model 1+Smoking, total cholesterol, HDL-cholesterol, systolic BP and BP medication (Framingham Risk Score Factors).
Model 3: Model 2+occupation, BMI, HRT use, past physical activity, current/previous CVD disease, non-ASA NSAIDs and glucose levels.
BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; HDL, High-density lipoprotein; HRT, hormone replacement therapy; NSAIDs, non-steroidal anti-inflammatory drugs; OA, osteoarthritis; ROA, radiographic osteoarthritis.
looking at the effect of knee and hand pain with and without ROA on all-cause and disease-specific mortality in middle-aged women. Participants’ selection to enter this study was not based on symptomatology or radiographic features. The comparison group is part of the same population and has no radiographic disease at baseline or side-specific pain. With comprehensive baseline data, we adjusted our analysis for potentially important multiple confounders, including all risk factors from the Framingham Heart Study. We performed a sensitivity analysis with a radiographic hand OA defined as the K/L score ≥2 in at least two joints, and this did not attenuate our findings.

Some potential limitations are worth mentioning. Findings of this study are limited to middle-aged and predominantly Caucasian women. In multivariable analysis of groups, we used baseline values of covariates, but those values may change over time and have time-dependent effects on OA and mortality outcomes that we would not be able to comment on in this analysis. This likely is underestimated the absolute risk of the exposure groups due to the fact that participants from the control group (ROA/−Pain−) remain in the original group even if they develop pain and/or ROA over time. In this study all exposure categories have this immortal time period. The other important limitation of this study is the fact that radiographs of the hands and knees were taken 3 years before knee and hand pain assessment. To mitigate against this, outcomes were measure from year 3 onwards. The PA and function is another potential residual confounding. We performed a sensitivity analysis using an available crude measures of PA that, when adjusted for, did not attenuate the findings.

In conclusion, knee pain with or without ROA in middle-aged women is associated with an increased all-cause and CVD mortality only. The highest risk was found in subjects with both ROA and knee pain. In addition, there was no association between hand pain, with or without ROA, and all-cause and specific-death mortality. The link behind this relationship is not completely understood. Further research analysing longitudinal differences in the groups’ characteristics associated with CVD mortality is required to identify potential underlying mechanisms. Additional studies of men-only or mixed gender cohorts are needed to confirm generalisability of these findings.

Twitter Follow Stefan Kluzek at @stefan.qz

Acknowledgements Dr Antonella Delmestri, Dr Anushka Soni, Alison Turner, Dr Daniel Prieto Alhambra, Dr Kassim Javid and Dr Anjali Shah.

Contributors Authors who made substantial contributions to conception and design, analysis, data interpretation and drafting and/or revising the article: SK, MTS-S, KML, AJ, CC, JN and NKA. Authors who made a substantial contribution to acquisition of data: TDS, DH, KML and NKA.

Funding This study was supported financially by the Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis (Grant reference 20194).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The Outer North East London Research Ethics Committee approved the study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement For information about the access to the Chingford 1000 Women Study data, please email chingford@nhrdom.ox.ac.uk.

REFERENCES

1 March L, Smith EU, Hoy DG, et al. Burden of disability due to musculoskeletal (MSK) disorders. Best Pract Res Clin Rheumatol 2014;28:353–66.

2 Turkiewicz A, Gerhardsson de Verdier M, Engstroem G, et al. Prevalence of knee pain and knee OA in southern Sweden and the proportion that seeks medical care. Rheumatology (Oxford) 2015;54:827–35.

3 Cullford DJ, Maskell J, Kiran A, et al. The lifetime risk of total hip and knee arthroplasty: results from the UK general practice research database. Osteoarthritis Cartilage 2012;20:519–24.

4 Haugen IK, Englund M, Allabadi P, et al. Prevalence, incidence and progression of hand osteoarthritis in the general population: the Framingham Osteoarthritis Study. Ann Rheum Dis 2011;70:1581–6.

5 Koskiniemi A, Vuolteenaho K, Miolanen T, et al. Resistin as a factor in osteoarthritis: synovial fluid resistin concentrations correlate positively with interleukin 6 and matrix metalloproteinases MMP-1 and MMP-3. Scand J Rheumatol 2014;43:249–53.

6 Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33–42.

7 Sannaus PO, Jones G, Blizzard L, et al. Associations between serum levels of inflammatory markers and change in knee pain over 5 years in older adults: a prospective cohort study. Ann Rheum Dis 2013;72:535–40.

8 Fowler-Brown A, Kim DH, Shi L, et al. The Mediating Effect of Leptin on the Relationship Between Body Weight and Knee Osteoarthritis in Older Adults. Arthritis Rheumatol 2015;67:169–75.

9 Kavonnen-Gutierrez CA, Harlow SD, Mancuso P, et al. Association of levitil levels with radiographic knee osteoarthritis among a cohort of middle age women. Arthritis Care Res (Hoboken) 2013;65:936–44.

10 Abu-Farha M, Behbehani K, Elkum N. Comprehensive analysis of circulating adipokines and hsCRP association with cardiovascular disease risk factors and metabolic syndrome in Arabs. Cardiovasc Diabetol 2014;13:76.

11 Allison MA, Jenny NS, McClelland RL, et al. The associations of adipokines with selected markers of the renin-angiotensin-aldosterone system: the multi-ethnic study of atherosclerosis. J Hum Hypertens 2015;29:127–33.

12 Ntanos G, Gatselis NK, Makaritsis K, et al. Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis 2013;227:216–21.

13 Illyasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413–18.

14 Rahman MM, Kopeca JA, Anis AH, et al. Risk of cardiovascular disease in patients with osteoarthritis: a prospective longitudinal study. Arthritis Care Res (Hoboken) 2013;65:1951–8.

15 Puenpatom RA, Victor TW. Increased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data. Postgrad Med 2009;129:1–20.

16 Kluzek S, Newton JL, Arden NK. Is osteoarthritis a metabolic disorder? Br Med Bull 2015;115:111–21.

17 Nüesch E, Dieppe P, Reichenbach S, et al. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011;342:d1165.

18 Liu Q, Niu J, Huang J, et al. Knee Osteoarthritis and All-cause Mortality: The Wuxuan Osteoarthritis Study. Osteoarthritis Cartilage 2015;23:1154–7.

19 Barbour KE, Lui LY, Nevitt MC, et al. Study of Osteoporotic Fractures Research Group. Hip osteoarthritis and the risk of all-cause and disease-specific mortality in older women: population-based cohort study. Arthritis Rheumatol 2015;67:1798–805.

20 Haara MM, Helliovaara M, Kroger H, et al. Osteoarthritis in the carpometacarpal joint of the thumb: Prevalence and associations with disability and mortality. J Bone Joint Surg Am 2004;86-A:1452–7.

21 Haara MM, Manninen P, Kroger H, et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis 2003;62:1511–8.

22 Haugen IK, Ramachandran VS, Misra D, et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham Heart Study. Ann Rheum Dis 2015;74:74–81.

23 Hart DJ, Spector TD. The relationship of obesity, fat distribution and osteoarthritis in women in the general population: the Chingford Study. J Rheumatol 1993;20:331–5.

24 Hart D, Spector T, Egger P, et al. Defining osteoarthritis of the hand for epidemiological studies: the Chingford Study. Ann Rheum Dis 1994;53:220–3.

25 Spector TD, Cooper C, Cushnagham J, et al. A radiographic atlas of knee osteoarthritis. London: Springer Verlag, 1992.

26 Hart DJ, Doyle DV, Spector TD. Incidence and risk factors for radiographic knee osteoarthritis in middle-aged women: the Chingford Study. Arthritis Rheum 1999;42:117–24.

27 Spector TD, Hart DJ, Byrne J, et al. Definition of osteoarthritis of the knee for epidemiological studies. Ann Rheum Dis 1993;52:790–4.

28 Soni A, Kiran A, Hart DJ, et al. Prevalence of reported knee pain over twelve years in a community-based cohort. Arthritis Rheum 2012;64:1145–52.

29 D’Agostino RR Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.

Kluzek S, et al. Ann Rheum Dis 2016;75:1749–1756. doi:10.1136/annrheumdis-2015-208056
Clinical and epidemiological research

30 Hart DJ, Doyle DV, Spector TD. Association between metabolic factors and knee osteoarthritis in women: the Chingford Study. J Rheumatol 1995;22:1118–23.

31 Cerhan JR, Wallace RB, el-Khoury GY, et al. Decreased survival with increasing prevalence of full-body, radiographically defined osteoarthritis in women. Am J Epidemiol 1995;141:225–34.

32 Hochberg MC. Mortality in osteoarthritis. Clin Exp Rheumatol 2008;26(Suppl 51):S120–4.

33 Hawker GA, Croxford R, Bierman AS, et al. All-cause mortality and serious cardiovascular events in people with hip and knee osteoarthritis: a population-based cohort study. PLoS One 2014;9:e91286.

34 Liu R, Kwok WY, Vliet Vlieland TP, et al. Mortality in osteoarthritis patients. Scand J Rheumatol 2015;44:70–3.

35 Zhang Y, Neogi T, Hunter D, et al. What effect is really being measured? An alternative explanation of paradoxical phenomena in studies of osteoarthritis progression. Arthritis Care Res (Hoboken) 2014;66:658–61.

36 Gonzalez EB. Nonsteroidal anti-inflammatory drugs did not increase risk for all-cause mortality in osteoarthritis. ACP J Club 2007;146:77.

37 Sui X, LaMonte MJ, Laditka JN, et al. Cardiorespiratory fitness and adiposity as mortality predictors in older adults. JAMA 2007;298:2507–16.

38 Dunlop DD, Song J, Semanik PA, et al. Objective physical activity measurement in the osteoarthritis initiative: are guidelines being met? Arthritis Rheum 2011;63:3372–82.

39 Bas S, Finch A, Puaskas GJ, et al. Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee. Int Orthop 2014;38:2577–83.

40 Kluzek S, Arden NK, Newton J. Adipokines as potential prognostic biomarkers in patients with acute knee injury. Biomarkers 2015;1–7.

41 Hoeven TA, Kavoussi M, Ikram AM, et al. Markers of atherosclerosis in relation to presence and progression of knee osteoarthritis: a population-based cohort study. Rheumatology (Oxford) 2015;54:1692–8.

42 Golbidi S, Laher I. Exercise induced adipokine changes and the metabolic syndrome. J Diabetes Res 2014;2014:726861.

43 Stanford KI, Middelbeek RJ, Goodyear LJ. Exercise Effects on White Adipose Tissue: Beiging and Metabolic Adaptations. Diabetes 2015;64:2361–8.

44 Stanford KI, Middelbeek RJ, Townsend KL, et al. A novel role for subcutaneous adipose tissue in exercise-induced improvements in glucose homeostasis. Diabetes 2015;64:2002–14.

45 Power JD, Bradley EM, French MR, et al. Fatigue in osteoarthritis: a qualitative study. BMC Musculoskelet Disord 2008;9:63.

46 Sale JE, Gignac M, Hawker G. How “bad” does the pain have to be? A qualitative study examining adherence to pain medication in older adults with osteoarthritis. Arthritis Rheum 2006;55:272–8.

47 Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev 2015;1:CD004376.

48 Williamson W, Kluzek S, Roberts N, et al. Behavioural physical activity interventions in participants with lower-limb osteoarthritis: a systematic review with meta-analysis. BMJ Open 2015;5:e007642.

49 Webster F, Perruccio AV, Jenkinson R, et al. Understanding why people do or do not engage in activities following total joint replacement: a longitudinal qualitative study. Osteoarthritis Cartilage 2015;23:860–7.

50 Shariff SZ, Cuerden MS, Jain AK, et al. The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008;19:841–3.